Literature DB >> 11488626

A microtiter plate assay for polyglutamine aggregate extension.

V Berthelier1, J B Hamilton, S Chen, R Wetzel.   

Abstract

Polyglutamine (polyGln) aggregates are neuropathological markers of expanded CAG repeat disorders, and may also play a critical role in the development of these diseases. We have established a highly sensitive, fast, reproducible, and specific assay capable of monitoring aggregate-dependent deposition of polyglutamine peptides. This assay allows detailed studies on various aspects of aggregation kinetics, and also makes possible the detection and quantitation of low levels of "extension-competent" aggregates. In the simplest form of this assay, polyGln aggregates are made from chemically synthesized peptides and immobilized onto microplate wells. These wells are incubated for different times with low concentrations of a soluble biotinylated polyGln peptide. Europium-streptavidin complexation of the immobilized biotin, followed by time-resolved fluorescence detection of the deposited europium, allows us to calculate the rate (fmol/h) of incorporation of polyGln peptides into polyGln aggregates. This assay will make possible basic studies on the assembly mechanism of polyGln aggregates and on critical features of the reaction, such as polyGln length dependence. The assay also will be a valuable tool for screening and characterizing anti-aggregation inhibitors. It will also be useful for detection and quantitation of aggregation-competent polyGln aggregates in biological materials, which may prove to be of critical importance in understanding the disease mechanism. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11488626     DOI: 10.1006/abio.2001.5217

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  8 in total

1.  A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila.

Authors:  Barbara L Apostol; Alexsey Kazantsev; Simona Raffioni; Katalin Illes; Judit Pallos; Laszlo Bodai; Natalia Slepko; James E Bear; Frank B Gertler; Steven Hersch; David E Housman; J Lawrence Marsh; Leslie Michels Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-01       Impact factor: 11.205

Review 2.  Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence.

Authors:  Ronald Wetzel
Journal:  J Mol Biol       Date:  2012-01-27       Impact factor: 5.469

3.  Stable polyglutamine dimers can contain β-hairpins with interdigitated side chains-but not α-helices, β-nanotubes, β-pseudohelices, or steric zippers.

Authors:  Markus S Miettinen; Luca Monticelli; Praveen Nedumpully-Govindan; Volker Knecht; Zoya Ignatova
Journal:  Biophys J       Date:  2014-04-15       Impact factor: 4.033

4.  Assays for studying nucleated aggregation of polyglutamine proteins.

Authors:  Murali Jayaraman; Ashwani K Thakur; Karunakar Kar; Ravindra Kodali; Ronald Wetzel
Journal:  Methods       Date:  2011-01-11       Impact factor: 3.608

5.  Structural properties of Abeta protofibrils stabilized by a small molecule.

Authors:  Angela D Williams; Matt Sega; Maolian Chen; Indu Kheterpal; Merav Geva; Valerie Berthelier; David T Kaleta; Kelsey D Cook; Ronald Wetzel
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-09       Impact factor: 11.205

6.  polyglutamine aggregation nucleation: thermodynamics of a highly unfavorable protein folding reaction.

Authors:  Anusri M Bhattacharyya; Ashwani K Thakur; Ronald Wetzel
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-17       Impact factor: 11.205

7.  Modified single-stranded oligonucleotides inhibit aggregate formation and toxicity induced by expanded polyglutamine.

Authors:  Hetal Parekh-Olmedo; Jin Wang; James F Gusella; Eric B Kmiec
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

8.  Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation.

Authors:  Songming Chen; Frank A Ferrone; Ronald Wetzel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-19       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.